Caribou Biosciences (CRBU)

$2.49

+0.05

(+2.05%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $2.45
    $2.57
    $2.49
    downward going graph

    1.61%

    Downside

    Day's Volatility :4.67%

    Upside

    3.11%

    downward going graph
  • $1.50
    $8.33
    $2.49
    downward going graph

    39.76%

    Downside

    52 Weeks Volatility :81.99%

    Upside

    70.11%

    downward going graph

Returns

PeriodCaribou BiosciencesSector (Health Care)Index (Russel 2000)
3 Months
-34.23%
6.5%
0.0%
6 Months
-55.31%
7.1%
0.0%
1 Year
-63.31%
9.8%
0.0%
3 Years
-85.43%
14.2%
-20.2%

Highlights

Market Capitalization
204.1M
Book Value
$3.8
Earnings Per Share (EPS)
-1.38
Wall Street Target Price
17.25
Profit Margin
0.0%
Operating Margin TTM
-1893.87%
Return On Assets TTM
-21.7%
Return On Equity TTM
-37.09%
Revenue TTM
33.4M
Revenue Per Share TTM
0.41
Quarterly Revenue Growth YOY
-30.599999999999998%
Gross Profit TTM
-68.4M
EBITDA
-127.3M
Diluted Eps TTM
-1.38
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.84
EPS Estimate Next Year
-2.06
EPS Estimate Current Quarter
-0.41
EPS Estimate Next Quarter
-0.43

Analyst Recommendation

Buy
    86%Buy
    13%Hold
    0
    0%Sell
Based on 15 Wall street analysts offering stock ratings for Caribou Biosciences(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
13
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 592.77%

Current $2.49
Target $17.25

Company Financials

FY19Y/Y Change
Revenue
5.8M
-
Net Income
-23.4M
-
Net Profit Margin
-404.82%
-
FY20Y/Y Change
Revenue
12.4M
↑ 113.56%
Net Income
-34.3M
↑ 46.42%
Net Profit Margin
-277.55%
↑ 127.27%
FY21Y/Y Change
Revenue
9.6M
↓ 22.35%
Net Income
-66.9M
↑ 95.07%
Net Profit Margin
-697.26%
↓ 419.71%
FY22Y/Y Change
Revenue
13.9M
↑ 44.31%
Net Income
-99.4M
↑ 48.56%
Net Profit Margin
-717.79%
↓ 20.53%
FY23Y/Y Change
Revenue
34.5M
↑ 148.91%
Net Income
-102.1M
↑ 2.66%
Net Profit Margin
-296.05%
↑ 421.74%
Q4 FY22Q/Q Change
Revenue
3.7M
↑ 11.78%
Net Income
-27.0M
↑ 0.87%
Net Profit Margin
-731.01%
↑ 79.07%
Q1 FY23Q/Q Change
Revenue
3.5M
↓ 5.15%
Net Income
-25.0M
↓ 7.42%
Net Profit Margin
-713.51%
↑ 17.5%
Q2 FY23Q/Q Change
Revenue
3.8M
↑ 7.22%
Net Income
-29.5M
↑ 18.14%
Net Profit Margin
-786.13%
↓ 72.62%
Q3 FY23Q/Q Change
Revenue
23.7M
↑ 530.15%
Net Income
-10.0M
↓ 66.12%
Net Profit Margin
-42.27%
↑ 743.86%
Q4 FY23Q/Q Change
Revenue
3.6M
↓ 84.96%
Net Income
-34.5M
↑ 244.98%
Net Profit Margin
-969.79%
↓ 927.52%
Q1 FY24Q/Q Change
Revenue
2.4M
↓ 31.73%
Net Income
-41.2M
↑ 19.5%
Net Profit Margin
-1.7K%
↓ 727.78%
FY19Y/Y Change
Total Assets
61.9M
-
Total Liabilities
54.5M
-
FY20Y/Y Change
Total Assets
36.0M
↓ 41.8%
Total Liabilities
59.5M
↑ 9.2%
FY21Y/Y Change
Total Assets
442.4M
↑ 1127.2%
Total Liabilities
54.5M
↓ 8.33%
FY22Y/Y Change
Total Assets
373.8M
↓ 15.51%
Total Liabilities
72.9M
↑ 33.67%
FY23Y/Y Change
Total Assets
441.0M
↑ 17.98%
Total Liabilities
72.6M
↓ 0.45%
Q4 FY22Q/Q Change
Total Assets
373.8M
↓ 6.28%
Total Liabilities
72.9M
↓ 2.43%
Q1 FY23Q/Q Change
Total Assets
347.5M
↓ 7.04%
Total Liabilities
69.2M
↓ 5.08%
Q2 FY23Q/Q Change
Total Assets
349.6M
↑ 0.63%
Total Liabilities
80.2M
↑ 15.9%
Q3 FY23Q/Q Change
Total Assets
457.5M
↑ 30.85%
Total Liabilities
59.3M
↓ 26.11%
Q4 FY23Q/Q Change
Total Assets
441.0M
↓ 3.62%
Total Liabilities
72.6M
↑ 22.47%
Q1 FY24Q/Q Change
Total Assets
406.8M
↓ 7.74%
Total Liabilities
63.5M
↓ 12.45%
FY19Y/Y Change
Operating Cash Flow
-32.0M
-
Investing Cash Flow
27.2M
-
Financing Cash Flow
172.0K
-
FY20Y/Y Change
Operating Cash Flow
-33.2M
↑ 3.78%
Investing Cash Flow
6.4M
↓ 76.63%
Financing Cash Flow
1.7M
↑ 908.72%
FY21Y/Y Change
Operating Cash Flow
-32.5M
↓ 2.1%
Investing Cash Flow
-176.4M
↓ 2872.23%
Financing Cash Flow
433.4M
↑ 24881.5%
FY22Y/Y Change
Operating Cash Flow
-91.0M
↑ 179.73%
Investing Cash Flow
-93.2M
↓ 47.14%
Financing Cash Flow
2.1M
↓ 99.51%
Q4 FY22Q/Q Change
Operating Cash Flow
-25.0M
↑ 11.92%
Investing Cash Flow
1.2M
↓ 114.03%
Financing Cash Flow
127.0K
↓ 80.58%
Q1 FY23Q/Q Change
Operating Cash Flow
-27.9M
↑ 11.56%
Investing Cash Flow
20.7M
↑ 1669.49%
Financing Cash Flow
1.6M
↑ 1192.91%
Q2 FY23Q/Q Change
Operating Cash Flow
-15.2M
↓ 45.65%
Investing Cash Flow
11.1M
↓ 46.56%
Financing Cash Flow
17.6M
↑ 970.1%

Technicals Summary

Sell

Neutral

Buy

Caribou Biosciences is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Caribou Biosciences
Caribou Biosciences
50.62%
-55.31%
-63.31%
-85.43%
-85.05%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Caribou Biosciences
Caribou Biosciences
NA
NA
NA
-1.84
-0.37
-0.22
NA
3.8
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Caribou Biosciences
Caribou Biosciences
Buy
$204.1M
-85.05%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Caribou Biosciences

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 23.66M → 2.42M (in $), with an average decrease of 58.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -10.00M → -41.23M (in $), with an average decrease of 132.2% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 124.9%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 271.9%

Institutional Holdings

  • BlackRock Inc

    7.76%

  • Partner Fund Management LP

    7.18%

  • State Street Corporation

    7.03%

  • Avidity Partners Management LP

    6.41%

  • Vanguard Group Inc

    4.55%

  • Point72 Asset Management, L.P.

    3.97%

Company Information

caribou biosciences is a leading biotechnology company in genome engineering. we develop technology-based solutions for cellular engineering and analysis based on the crispr-cas9 technology platform. cas9, when paired with a guide rna, cuts double-stranded dna allowing for specific changes to dna. these site-specific dna modifications can be utilized to carry out sophisticated gene knock-outs or knock-ins. caribou's technologies mark a revolutionary development that allows scientists to engineer nearly any part of any genome with extreme flexibility. forbes magazine has called cas9 the protein that "could change biotech forever"​ and the new york times has noted that "the pace of new discoveries and applications is dizzying."​ caribou's tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. interested in joining our team? please contact us at jobs at cariboub

Organization
Caribou Biosciences
Employees
158
CEO
Dr. Rachel E. Haurwitz Ph.D.
Industry
Services

Discover More

FAQs